Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring

Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Monitoring Clinical Guidelines January 2020 Review date: December 2020The Royal College of Ophthalmologists (RCOphth) is the professional body for eye doctors, who are medically qualified and have undergone or are undergoing specialist training in the treatment and management of eye disease, including surgery. As an independent charity, we pride (...) Interpretation of Monitoring Results 7 2.5 Management of Patients with Possible Retinopathy 8 2.6 Management of Patients with Definite Toxicity 8 2.7 Termination of Monitoring 8 2.8 Organisation of Services 8 2.9 Work Commitment 9 3. Monitoring for hydroxychloroquine retinopathy: Lay Summary 10 4. Introduction 12 4.1 Population to whom the Guideline applies e.g. the age range, gender, clinical description (ICD10) and co-morbidity (ICD10) and any exclusions 13 4.2 Paediatric Indications for Monitoring 13 4.3

2021 Royal College of Ophthalmologists

2. A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of combinations of lopinavir/ritonavir, azithromycin, doxycycline, & hydroxychloroquine for COVID-19 Full Text available with Trip Pro

A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of combinations of lopinavir/ritonavir, azithromycin, doxycycline, & hydroxychloroquine for COVID-19 CDEI - A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of lopinavir/ritonavir-azithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections — CDEI Open Menu (...) Close Menu Open Menu Close Menu Mar 11 Written By Citation: Purwati , Budiono, Rachman, B. E., Miatmoko, A., Lardo, S., Purnama, Y. I., Laely, M., Rochmad, I., ... & Indrayani, Y. (2021). A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of lopinavir/ritonavir-azithromycin, lopinavir/ritonavir-doxycycline, and azithromycin-hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections. Biochemistry research

2021 Covid-19 Drug Evidence Initiative

3. A cluster-randomized trial of hydroxychloroquine for prevention of covid-19 Full Text available with Trip Pro

A cluster-randomized trial of hydroxychloroquine for prevention of covid-19 CDEI - A cluster-randomized trial of hydroxychloroquine for prevention of covid-19 — CDEI Open Menu Close Menu Open Menu Close Menu Dec 30 Written By Citation: Mitjà, O. , Corbacho-Monné, M., Ubals, M., Alemany, A., Suñer, C., & Tebé, C. et al. (2020). A cluster-randomized trial of hydroxychloroquine for prevention of covid-19. New England Journal Of Medicine . doi: 10.1056/nejmoa2021801 DOI: Journal impact factor (...) : 74.699 (New England Journal of Medicine) Full PICO and Limitations in text: Population: 2314 asymptomatic adults ≥18 years old with a recent history of close-contact exposure to a PCR-confirmed case patient with COVID-19, and an increased risk of infection (health care worker, household contact, a nursing home worker, or a nursing home resident). Intervention and Comparator Intervention: 1116 patients. Hydroxychloroquine (800mg once, followed by 400mg daily for 6 days). Comparator: 1198 patients

2021 Covid-19 Drug Evidence Initiative

4. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate COVID-19

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate COVID-19 CDEI - A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19) — CDEI Open Menu Close Menu Open Menu Close Menu Dec 15 Written By Citation (...) : Chen, C. P. , Lin, Y. C., Chen, T. C., Tseng, T. Y., Wong, H. L., Kuo, C. Y., ... & Liao, C. S. (2020). A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PloS one , 15 (12), e0242763. DOI: Journal Impact Factor: 2.740 (PloS one) Full PICO and Limitations in text: Population: 33 adult (20-79 years) patients diagnosed SARS-CoV-2

2021 Covid-19 Drug Evidence Initiative

5. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial Full Text available with Trip Pro

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clin Infect Dis Actions . 2020 Oct 17;ciaa1571. doi: 10.1093/cid/ciaa1571. Online ahead of print. Hydroxychloroquine as pre-exposure

2021 EvidenceUpdates

6. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients Full Text available with Trip Pro

Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 (...) : 10.1093/ofid/ofaa446. eCollection 2020 Oct. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA. 2 Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, USA. 3 Department of Population Health, New

2021 EvidenceUpdates

7. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 Full Text available with Trip Pro

Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: Get (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Open Forum Infect Dis Actions . 2020 Oct 19;7(11):ofaa500. doi: 10.1093/ofid/ofaa500. eCollection 2020 Nov. Safety of Hydroxychloroquine Among Outpatient Clinical

2021 EvidenceUpdates

8. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19 Full Text available with Trip Pro

Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19 CDEI - Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Nov 22 Written By Citation: Self, W. , Semler, M., Leither, L., Casey, J., Angus, D., & Brower, R. et al. (2020). Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19. JAMA . DOI: Journal impact factor (...) : 45.540 (JAMA) Clinical trial registry link : Full PICO and Limitations in text: Population: 479 Patients > 18 years old, with laboratory confirmed SARS-CoV-2, with symptoms of respiratory illness for < 10 days and hospitalized for under 48 hours. Intervention and Comparator Intervention: 242 patients. Hydroxychloroquine (400 mg po BID x 1 day, then 200 mg BID x 4 days). Comparator: 237 patients. Placebo (same dosing regimen as above). Outcomes: Primary outcomes: Clinical status 14 days after

2020 Covid-19 Drug Evidence Initiative

9. Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial Full Text available with Trip Pro

Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial CDEI - Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial — CDEI Open Menu Close Menu Open Menu Close Menu Nov 17 Written By Citation: Brown, S. M. , Peltan, I., Kumar, N., Leither, L., Webb, B. J., Starr, N., . . . Greene, T. (2020). Hydroxychloroquine vs. azithromycin (...) for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial. Annals of the American Thoracic Society . DOI: Journal impact factor: 4.836 (Annals of the American Thoracic Society) Clinical trial registry link : Full PICO and Limitations in text: Population: 85 hospitalized patients with laboratory-confirmed COVID-19 and active symptoms. Intervention and Comparator Intervention: 42 patients. Hydroxychloroquine 400mg BID on day 1, then 200mg BID for 4 days. Comparator: 43

2020 Covid-19 Drug Evidence Initiative

10. Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial Full Text available with Trip Pro

Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial CDEI - Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial — CDEI Open Menu Close Menu Open Menu Close Menu Dec 12 Written By Citation: Abd-Elsalam, S. , Soliman, S., Esmail, E. S., Khalaf, M., Mostafa, E. F., Medhat, M. A., . . . Hassany, S. M. (2020). Do zinc supplements enhance the clinical efficacy of hydroxychloroquine (...) ?: A randomized, multicenter trial. Biological Trace Element Research. DOI: Journal impact factor: 2.639 (Biological Trace Element Research) Clinical trial registry link : Full PICO and Limitations in text: Population: 191 hospitalized adult (≥18) patients with PCR confirmed COVID-19 infection. Intervention and Comparator Intervention: 96 patients. Zinc Sulfate (220mg/50mg elemental zinc orally twice daily) plus Hydroxychloroquine (400mg orally twice daily on day 1, then 200mg orally twice daily for 5 days

2020 Covid-19 Drug Evidence Initiative

11. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 Full Text available with Trip Pro

Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 CDEI - Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19 — CDEI Open Menu Close Menu Open Menu Close Menu Dec 13 Written By Citation: Omrani, A. S. , Pathan, S. A., Thomas, S. A., Harris, T. R., Coyle, P. V., Thomas, C. E., ... & Elmalik, A. (2020). Randomized (...) double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine , 29 , 100645. DOI: Clinical trial registry link : Full PICO and Limitations in text: Population: 456 non-hospitalized adult (>18 years) patients diagnosed with PCR-confirmed SARS-CoV-2 infection and with no to mild symptoms. Interventions and Comparator Intervention: 152 patients. Hydroxychloroquine (HCQ) with placebo - Hydroxychloroquine 200mg q8h

2020 Covid-19 Drug Evidence Initiative

12. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis Full Text available with Trip Pro

Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) of print. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis , , , Affiliations Expand Affiliations 1 Department of Cardiology, VMMC & Safdarjung Hospital, New Delhi, India. 2 Department of Cardiology, Fortis Hospital, Mohali, Punjab, India. 3 Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 4 Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education

2020 EvidenceUpdates

13. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020 Full Text available with Trip Pro

Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020 Redirecting

2020 One health

14. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial Full Text available with Trip Pro

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial CDEI - Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: A randomized trial — CDEI Open Menu Close Menu Open Menu Close Menu Sep 28 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media (...) as established information (medRxiv). Citation: Rajasingham, R. , Bangdiwala, A. S., Nicol, M. R., … Lofgren, S. M. (2020). Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: A randomized trial. MedRxiv DOI: Full PICO and Limitations in text: Population: 1483 healthcare workers aged 18 years or older with ongoing exposure to persons with COVID-19. InterventionS and Comparator Intervention 1: 494 patients. Hydroxychloroquine 400mg divided into two 200mg doses separated by 6-8

2020 Covid-19 Drug Evidence Initiative

15. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis Full Text available with Trip Pro

Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Neurology, All India Institute of Medical Sciences, New Delhi, 110029, India. 2 Department of Community Medicine, NDMC Medical College, New Delhi, India. 3 Clinical Hematology, All India Institute of Medical Sciences, New Delhi, 110029, India. 4 Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India. 5 Pulmonary Medicine

2020 EvidenceUpdates

16. Hydroxychloroquine: did COVID-19 change GP prescribing?

Hydroxychloroquine: did COVID-19 change GP prescribing? Hydroxychloroquine: did COVID-19 change GP prescribing? - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Health professionals also need to stay up to date with the latest evidence as it emerges. Our information hub has important information for everyone. Featured topics 02 Sep 2020 06 Aug 2020 03 Aug 2020 24 Jun 2020 09 Jun 2020 Featured article (...) address* Password* Log in Rate us How likely is it that you would recommend our site to a friend? Please help us to improve our services by answering the following question How likely is it that you would recommend our site to a friend? 0 1 2 3 4 5 6 7 8 9 10 0 = Not likely at all 10 = Extremely likely Please feel free to tell us why SUBMIT Hydroxychloroquine: did COVID-19 change GP prescribing? A study looking at prescribing patterns for hydroxychloroquine during the first months of the COVID-19

2020 National Prescribing Service Limited (Australia)

17. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19 Full Text available with Trip Pro

A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19 A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Cureus Actions . 2020 Aug 24;12(8):e10005. doi: 10.7759/cureus.10005. A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19 , , , , , , , , Affiliations Expand Affiliations 1 Medicine, St. John's Episcopal

2020 EvidenceUpdates

19. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Full Text available with Trip Pro

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine (...) and 3155 to receive usual care. The primary outcome was 28-day mortality.The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients

2020 NEJM

20. Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies Full Text available with Trip Pro

Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies | medRxiv Search for this keyword Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies Fernanda Talarico , Sucheta Chakravarty , Yang S. Liu , Andrew Greenshaw (...) Psiquiatria e Ciências do Comportamento, Laboratory of Molecular Psychiatry and Bipolar Disorder Program, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul , Porto Alegre, RS, Brazil Bo Cao 1 Department of Psychiatry, University of Alberta, Edmonton , AB, Canada For correspondence: Abstract Chloroquine and hydroxychloroquine are commonly used drugs in the treatment of malaria as well as chronic diseases, such as rheumatoid arthritis, and systemic lupus erythematosus. Although

2020 Cold Spring Harbor Laboratory